Preeclampsia and COVID-19: results from the INTERCOVID prospective longitudinal study

doi:10.1016/j.ajog.2021.05.014

PMC full text:

Am J Obstet Gynecol. 2021 Sep; 225(3): 289.e1–289.e17.

Published online 2021 Jun 26. doi: 10.1016/j.ajog.2021.05.014

Copyright/LicenseRequest permission to reuse: Copyright © 2021 Published by Elsevier Inc.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

<< PrevFigure 1Next >>

Figure 1

An external file that holds a picture, illustration, etc.
Object name is gr1_lrg.jpg

Kaplan-Meier curves

For gestational age at diagnosis of COVID-19, stratified by preeclampsia status during pregnancy. Blue represents no preeclampsia; red represents preeclampsia. Cox model hazard ratio, 1.49 (95% CI, 1.12–1.97). One woman was diagnosed with COVID-19 at ≤13 weeks’ gestation; 34 were diagnosed from >13 to ≤26 weeks’ gestation; 636 were diagnosed at >26 weeks’ gestation; for 35 women the information about the gestational age at diagnosis was not available.

Papageorghiou et al. Preeclampsia and COVID-19. Am J Obstet Gynecol 2021.

Figure 1

Images in this article

Click on the image to see a larger version.